Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.

Clinical pharmacology and therapeutics - 1 Sept 2001

Thijssen H H, Drittij M J, Vervoort L M, de Vries-Hanje J C

Abstract excerpt

OBJECTIVE: Our objective was to study the pharmacokinetics of R - and S -acenocoumarol in a subject who was highly sensitive to the anticoagulant effect of acenocoumarol. The subject was found to be heterozygous for CYP2C9*3. METHODS: The plasma pharmacokinetics of the acenocoumarol enantiomers was established after an oral dose of 8 mg of racemic acenocoumarol. Urine was collected to establish the formation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Drug Hypersensitivity

Share to Stereoisomerism

Share to Steroid 16-alpha-Hydroxylase

Share to Steroid Hydroxylases

Source

Identifiers

PMID: 11557918
DOI: 10.1067/mcp.2001.117936

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.PMID 11557918Read ↗

Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.Semantic proximity Read ↗

The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.Semantic proximity Read ↗

CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.Semantic proximity Read ↗

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Semantic proximity Read ↗

Pharmacogenetics of warfarin elimination and its clinical implications.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol pharmacodynamics.Semantic proximity Read ↗

Acenocoumarol stabilization is delayed in CYP2C93 carriers.Semantic proximity Read ↗

Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.Semantic proximity Read ↗

Genetic association between sensitivity to warfarin and expression of CYP2C9*3.Semantic proximity Read ↗

Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.